MedTrace Logo

TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)

NCT07732010 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-07-28

No results posted yet for this study

Summary

The purpose of this research study is to determine the effectiveness of TRYPTYR as a treatment for Dry Eye Disease. The primary efficacy variable is change from baseline in the Ocular Surface Disease Index (OSDI) at week 2. The co-primary efficacy variables are change from baseline in the National Eye Institute (NEI) scale of the cornea and NEI scale of the conjunctiva at 1 month (the third visit).

Conditions

  • Dry Eye Disease (DED)

Interventions

DRUG

TRYPTYR (Acoltremon ophthalmic solution 0.003%)

TRYPTYR will be administered one drop in each eye twice daily (once every 12 hours) for 30 days.

Sponsors & Collaborators

Principal Investigators

  • Giacomina Massaro-Giordano, MD · NYU Langone Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-06
Primary Completion
2027-04-20
Completion
2027-05-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07732010 on ClinicalTrials.gov